The pharma company Lupin reported a decrease in consolidated net profit by 22.19 percent to 1155.30 crore rupees in the September quarter. This decline was attributed to an exceptional expense item.
In the report submitted to stock exchange regulators, the company indicated that in the same period last fiscal year, net profit amounted to 1484.83 crore rupees. Operating revenue for the quarter under review reached 7827.26 crore rupees, exceeding the figure of 7047.51 crore rupees from the previous year.
Lupin's total expenses also increased to 6374.46 crore rupees in the current quarter compared to 5130.54 crore rupees for the same period last year. Furthermore, for the period from April to September 2027 fiscal year, the company's net profit decreased by 4.95 percent, amounting to 2572.28 crore rupees versus 2706.29 crore rupees the previous year.
During the six months ending September 30, 2026, Lupin Pharmaceuticals Inc USA, a subsidiary of the Group, settled an antitrust lawsuit for $316.28 crore (US$35.8 million) without admitting guilt or wrongdoing, as stated in the filings.
The company added that it continues to bear the remaining provision for future settlements related to similar cases. Meanwhile, the company's sales in the US for the September quarter amounted to 3020.2 crore rupees, which is 9.3 percent higher than 2762.4 crore rupees the previous year.
According to the IQVIA report for September 2026, Lupin remains the third-largest pharmaceutical player in both the US generics market and the overall US prescription market. Sales in India for the second quarter of the 2027 fiscal year reached 2383.6 crore rupees, which is 14.7 percent more than 2077.7 crore rupees in the second quarter of the 2026 fiscal year, accounting for 31 percent of Lupin's global sales.
Lupin's Managing Director, Nilesh Gupta, stated that the company demonstrated a strong first half of the 2027 fiscal year, supported by steady growth in key markets and maintained profitability. He noted that despite acknowledging short-term difficulties, management is confident in long-term growth prospects, which are supported by the strength of its portfolio, continuous investment in research and development, as well as commercial opportunities and unwavering focus on disciplined execution.



